(ED: the San Diego-based research center has a Chiluly glass sculpture, as pictured…)


January 24, 2013 | By 

Despite huge investments from Big Pharma, few new therapies are entering the market to treat chronic diseases like cancerdiabetes and Alzheimer’s. As age-related disorders increase because of longer life spans and greater awareness, there is a tremendous need for effective treatments for these diseases.

A new research center is hoping to bridge that gap between development and clinical application.

The La Jolla, CA-based Salk Institute for Biological Studies has landed a $42 million grant to establish the Helmsley Center for Genomic Medicine. The award, from The Leona M. and Harry B. Helmsley Charitable Trust, is the biggest in Salk’s history.

eBook: Facing Up to the Biosimilar Challenge: Preclinical and Beyond

Faced with a continuing economic crisis and an aging and increasingly obese population, healthcare providers are seeing where they can cut costs. Generics saved the U.S. healthcare system $192 billion in 2011 alone. To read more on this timely topic, download this eBook today.

Sign up for our FREE newsletter for more news like this sent to your inbox!Salk is hoping to use the grant money to hire an additional two researchers, invest in new technology and pursue new projects, especially in the areas of metabolism, inflammation-based diseases and stem cell research using iPS cells to model neurodegenerative diseases. Headed by Fred Gage, Inder Verma, Ronald Evans, Juan Carlos Izpisua Belmonte, Reuben Shaw and Marc Montminy, researchers at the new Helmsley Center will use genomic data in an effort to untangle the mysteries behind why molecular and genetic mechanisms go awry in chronic diseases.

Montminy, a professor in the Clayton Foundation Laboratories for Peptide Biology, said developing therapies for chronic disease has been challenging.

“One problem, especially for Alzheimer’s, is that getting neurons from patients is not practical. You can’t biopsy a brain without seriously affecting it,” Montminy told FierceBiotechResearch.

Another hurdle, Montminy said, is having animal models that mirror chronic diseases in humans. Diseases like diabetes and Parkinson’s change and develop over time, which makes them difficult to study in animals. And sometimes when changes or mutations occur in genes, they don’t cause illness right away but might later become activated because of stress or other factors.

The $42 million Helmsley gift brings the Salk Institute’s fundraising efforts to nearly $200 million, closer to its goal of $300 million, which the institute set late last year. Federal funding from the National Institutes of Health accounted for two-thirds of Salk’s budget in 2003, and last year that number dropped to less than 50%.

Read more: Salk Institute gets $42M grant to study chronic diseases, establish new genomic center – FierceBiotech Research http://www.fiercebiotechresearch.com/story/salk-institute-gets-42m-grant-study-chronic-diseases-establish-new-genomic/2013-01-24#ixzz2JxM2f6dI
Subscribe: http://www.fiercebiotechresearch.com/signup?sourceform=Viral-Tynt-FierceBiotech Research-FierceBiotech Research


No comments

Be the first one to leave a comment.

Post a Comment